Berkeley, California-based ADRO is a clinical stage biotech firm focused on developing technology platforms to trigger and sustain immune system responses against cancer. ADRO is set to price its IPO this Wednesday, April 15th; lead underwriters are BofA Merrill Lynch and Leerink Partners.
